(Q44078747)

29 November 2017

title

Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression (English)

1 reference

29 November 2017

1 reference

Bruce J Giantonio

1

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Nature Reviews Clinical Oncology

29 November 2017

published in

1 reference

29 November 2017

volume

6

1 reference

29 November 2017

issue

6

1 reference

29 November 2017

page(s)

311-312

1 reference

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

29 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.66

Resistance to chemotherapy in cancer: a complex and integrated cellular response

31 March 2020

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.66

Vascular endothelial growth factor: biology and therapeutic applications

31 March 2020

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.66

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19483736

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Modes of resistance to anti-angiogenic therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19483736

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antiangiogenic therapy for cancer: current and emerging concepts

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19483736

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2009.66

1 reference

29 November 2017

1 reference